Experts in allograft

Regen Medical is a new and integral part of the Joint Operations family. Our dedicated team was formed to support its customers within the burns, wound healing, plastic and regenerative.

Experts in allograft, Regen Medical is excited to be offering a ground-breaking product portfolio throughout the UK, including products from MiMedx®.

MiMedx is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics.

EpiFix® is a minimally manipulated, dehydrated, non-viable cellular amnion/chorion membrane allograft for homologous use in acute and chronic wound care, that contains multiple extracellular matrix proteins, growth factors, cytokines and other specialty proteins present in amniotic tissue to provide a barrier membranethat enhances healing.

90+% healing in Diabetic Foot Ulcers (DFU's) at 6 weeks14

185 regulatory proteins are contained in EpiFix5-7

71% healing in Venous Leg Ulcers (VLU's) at 16 weeks8

Average number of treatments to closure9

Clinical and scientific publications

The EpiFix® dehydrated human amnion/chorion membrane (dHACM) allograft is a minimally manipulated natural human amniotic membrane that provides a scaffold for cellular ingrowth, modulates inflammation and reduces scar tissue formation for enhanced healing.

Peer-reviewed publications have demonstrated that PURION processed dHACM recruits stem cells, promotes migration and modulates stem cell activity in vitro and in vivo compared to appropriate controls. EpiFix contains a large and diverse array of 285 regulatory proteins including growth factors, cytokines, and chemokines that are known to be therapeutic regulators of inflammation, angiogenesis and wound healing.

Peer-reviewed, published randomised controlled clinical trials demonstrate that PURION processed dHACM is an effective therapy for treatment of chronic wounds and to promote healing. With over 40 clinical and scientific publications on MiMedx products, the clinical efficacy and bioactivity is well-established.

VLU wounds are twice as likely to heal with Epifix than with standard of care alone8
1 Zelen CM, et al. Int Wound J. 2013 Oct; 10(5):502-7. 2 Zelen CM. J Wound Care. 2013Jul;22(7):347-8, 350-1. 3 Zelen CM, et al. Int Wound J. 2014 Apr; 11(2): 122-8. 4 Zelen CM, et al. Int Wound J. 2015 Dec; 12(6):724-32. 5 MM-RD-00072, Proteome Characterization of MiMedx Placental Tissue Products 6 Koob TJ, Lim JJ, Massee M, Zabek N, Denoziere G. Properties of dehydrated human amnion/chorion composite grafts: implications for wound repair and soft tissue regeneration. J Biomed Mater Res B Appl Biomater. 2014 Aug; l 02(6): 1353-62 7 lei J, Priddy LB, Lim JJ, Massee M, Koob TJ. Identification of Extracellular Matrix Components and Biological Factors in Micronized Dehydrated Human Amnion/Chorion Membrane. Adv Wound Care (New Rochelle). 2017 Feb 1;6(2):43-53 8 Bianchi, C., Cazzell, S., Vayser, D., Reyzelman, A. M., Dosluoglu, H., Tovmassian, G. and EpiFix VLU Study Group (2017). A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/ chorion membrane (EpiFix®) allograft for the treatment of venous leg ulcers. Int Wound J. doi: 10.  1111/iwj.12843. 9 Zelen CM, et al. Int Wound J. 2014 Apr; 11 (2): 122-8.